Adjuvant Development Program

This program aims to advance novel vaccine adjuvants toward licensure for human use. The program supports the optimization of adjuvant candidates; vaccine formulation and preclinical adjuvant pharmacology, toxicity, and efficacy studies.

Vaccines to prevent infectious diseases have saved millions of lives worldwide, yet there remains a need for new and improved vaccines against existing and emerging infections. Efforts to develop safe and effective vaccines increasingly involve the use of adjuvants — substances formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvant discovery and development play critical roles in NIAID vaccine development efforts.

Main Areas of Focus

  • To advance novel vaccine adjuvants toward licensure for human use
Content last reviewed on November 17, 2017